57 In the index

CX-516 CX516

An early experimental drug studied in small human trials for improving thinking in older adults and people with schizophrenia. It showed some modest promise, but it didn't last long enough in the body to be practical, and development moved on to newer, similar compounds instead.

Also known as Ampalex

Effects Focus

Routes Oral

Legal status Research chemical

WADA Not listed

3D Molecular Structure of C₁₄H₁₅N₃O

Drag to rotate · scroll to zoom

Chemistry

Formula: C14H15N3O
Molar mass: 241.29
CAS: 154235-83-3
PubChem CID: 148184

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not established (development discontinued)

Reported range Early trial doses up to 1600 mg/day, divided

Route Oral

Frequency Multiple times daily (per trial protocol)

Duration Trial durations of several weeks

Development of this early 'ampakine' was discontinued due to poor bioavailability and weak clinical effect; no legitimate current source or safety data.

Where this comes from Discontinued early-phase clinical trial data

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.